Importantly, the use of humanized CTLA4-knockin mice allowed us to interrogate the physiological consequences of targeting CTLA4 with a monoclonal antibody, ipilimumab, FDA-approved for various human cancers. The gene discussed is CTLA4; the disease is cancer.